Video

Dr Clarence Moore: Luspatercept Is a Positive Step Forward in Beta Thalassemia

Clarence Moore, PharmD, BCPS, BCOP, assistant professor at Shenandoah University in Ashburn, Virginia, discusses a new treatment option for beta thalassemia.

Transcript

What are the unmet needs for patients with beta thalassemia? What more needs to be done in terms of therapy options?

I think we are moving in the right direction. Luspatercept [Reblozyl] was FDA approved within the past year or so. So, I think we're moving right in the right direction. I know, historically, there hadn't been any real movement in the disease state itself. Having some form of medication to decrease blood transfusions in that patient population, I think, is huge. I think we're heading in the right direction. I know we'd always like to have more medications, but I think with the movements we're seeing right now, we're doing well.

In November 2019, the FDA approved Reblozyl as a treatment option for anemia in transfusion dependent patients. What are the benefits of having this additional therapy available?

So, having that additional therapy I think is great because to be able to actually decrease the amount of infusions that those patients potentially [need]. And that decreased amount required infusions changes the landscape of essentially what we've historically done in the beta thalassemia disease setting.

Related Videos
Screenshot of an interview with Amir Ali, PharmD, BCOP
1 expert in this video
1 expert in this video
Dr Cesar Davila-Chapa
1 expert in this video
1 expert in this video
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo